There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
Show figures in :Show figures in :
Data is unavailable
Data is unavailable
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Net worth | 2854.36 | 2586.18 | 2195.99 | 1908.31 | 1576.42 | 1296.33 | 1150.52 | 861.31 | 567.14 | 299.62 |
| Fixed assets | 5306.48 | 4319.16 | 2568.10 | 917.94 | 853.87 | 874.85 | 760.54 | 771.09 | 231.65 | 71.37 |
| Debt | 2421.66 | 2735.27 | 830.02 | 45.01 | 0.01 | - | 176.42 | 376.80 | 0.65 | 0.50 |
View detailed balance sheet
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 1065.01 | 486.01 | 291.74 | 378.26 | 375.36 | 271.17 | 223.00 | 234.64 | 200.21 | 131.48 |
| Investing | -79.97 | -1854.52 | -982.10 | -319.61 | -323.36 | 123.23 | -5.05 | -590.10 | -184.46 | -43.91 |
| Financing | -881.32 | 1379.68 | 688.03 | -44.70 | -82.40 | -334.59 | -221.05 | 363.21 | -23.66 | -83.70 |
Eris manufactures and markets prescription pharmaceuticals across specialty and super-specialty therapies, with leadership in cardio-metabolic care and growing portfolios in Dermatology, Women’s Health, Critical Care, Nephrology and Oncology .
As on March 31, 2025, Eris had 8 subsidiaries and 1 joint venture; only the number is disclosed here in line with your request .
The Group operates manufacturing across six globally accredited/compliant units in India, with facilities designed for EU-GMP, PIC/s and Latin American compliance; Swiss Parenterals is the international arm as Eris expands to RoW exports. Its Ahmedabad units were inspected by ANVISA, reflecting readiness for large international markets .
